Edgewise Therapeutics Thesis 2026: A Clinical-Stage Cardiomyopathy-and-Muscular-Dystrophy Compounder
Key Takeaways
- Edgewise Therapeutics (NASDAQ: EWTX), the Boulder-CO-headquartered Clinical-Stage-Biotech-Cardiomyopathy-and-Muscular-Dystrophy + emerging-multi-cycle-EDG-5506-and-EDG-7500-Phase-3-and-2 leader, closes FY2025 with selected various aggregate revenue ~$0M (pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development), adjusted EBITDA ~$-180 to -125M (Pre-Commercial-Biotech-Clinical-Development-Burn), adjusted EPS ~$-2.95 to -2.05 (pre-Commercial-Biotech-loss), net cash ~$0.55-0.75B (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027), and ~~62-65M shares under President & CEO Kevin Koch (since 2017-Founder-CEO + Founder-Edgewise-Therapeutics-Co-Founder + Former-Array-Biopharma-and-Tecan-and-Genentech-veteran).
- Operates substantial multi-cycle ~~100-130 employees + ~~Boulder-CO-HQ-Clinical-Development-Biotech-Office providing distinctive multi-cycle EDG-5506-Sevasemten + multi-cycle-emerging-EDG-7500-and-EDG-5506-Cardiomyopathy-and-Muscular-Dystrophy + multi-cycle-emerging-Clinical-Stage-Pipeline-Cardiomyopathy-and-Muscular-Dystrophy platform.
- Distinctive multi-cycle Edgewise-Therapeutics-and-Boulder-CO-and-Clinical-Stage-Biotech heritage: founded 2017 as Edgewise-Therapeutics-Kevin-Koch-Founder-and-Co-Founder + 2017-Edgewise-Therapeutics-Founder-Family-and-Co-Founder-Kevin-Koch + 2019-substantial-Series-B-Financing + 2020 NASDAQ Edgewise-Therapeutics-IPO ($175M proceeds providing distinctive Public-Listing-and-Clinical-Development-Funding) + 2021-substantial-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Phase-2-and-Phase-3-clinical-trials + 2024-substantial-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-substantial-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts.
- Distinctive multi-cycle Clinical-Stage-Biotech-Pipeline (~~0% pre-Commercial-Biotech-revenue, pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development + multi-cycle-emerging-EDG-5506-Sevasemten-Muscular-Dystrophy-Becker-and-DMD-Phase-3 + multi-cycle-emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2 + multi-cycle-emerging-Discovery-Pipeline) + Emerging-Other-Collaboration-and-Grant (~~0-1% pre-Commercial-Biotech-revenue) platform.
- Customer base: Pre-Commercial-Biotech-Clinical-Development (no customer base, pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development + multi-cycle-emerging-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Patient-and-Physician-and-Health-Plan-target).
- Pre-Commercial-Biotech (Not-Rated-Pre-Commercial-Biotech) balance sheet (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027 ~$0.55-0.75B), no-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn), FY2026 turns on EDG-5506-Sevasemten-Phase-3-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne-Clinical-Trial-Readout + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Clinical-Trial-Readout + emerging-Pipeline-Advancement + Kevin-Koch-Founder-CEO-strategic-execution.
Company Background
Edgewise Therapeutics (NASDAQ: EWTX), headquartered in Boulder, Colorado, is a Clinical-Stage-Biotech-Cardiomyopathy-and-Muscular-Dystrophy + emerging-multi-cycle-EDG-5506-and-EDG-7500-Phase-3-and-2 leader providing distinctive multi-cycle EDG-5506-Sevasemten + emerging-EDG-7500 services to substantial multi-cycle Pre-Commercial-Biotech-Clinical-Development-Patient-and-Physician-and-Health-Plan-target. The company has a distinctive multi-cycle Edgewise-Therapeutics-and-Boulder-CO-and-Clinical-Stage-Biotech heritage: founded 2017 as Edgewise-Therapeutics-Kevin-Koch-Founder-and-Co-Founder; 2019-substantial-Series-B-Financing; 2020 NASDAQ Edgewise-Therapeutics-IPO ($175M proceeds); 2021-substantial-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Phase-2-and-Phase-3-clinical-trials; 2024-substantial-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension; 2024-substantial-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts.
Multi-decade strategic-evolution: 2017 Edgewise-Therapeutics-Kevin-Koch-Founder-and-Co-Founder-founded; 2019-substantial-Series-B-Financing; 2020 NASDAQ-Edgewise-Therapeutics-IPO ($175M proceeds); 2021-substantial-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Phase-2-and-Phase-3-clinical-trials + 2024-substantial-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-substantial-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts; 2020-2025 substantial multi-cycle Pre-Commercial-Biotech-Clinical-Development-and-Cash-Runway-Extension-and-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2.
Under President & CEO Kevin Koch (since 2017-Founder-CEO + Founder-Edgewise-Therapeutics-Co-Founder + Former-Array-Biopharma-and-Tecan-and-Genentech-veteran), FY2025 closes with selected various aggregate revenue ~$0M (pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development), adjusted EBITDA ~$-180 to -125M (Pre-Commercial-Biotech-Clinical-Development-Burn), adjusted EPS ~$-2.95 to -2.05 (pre-Commercial-Biotech-loss), net cash ~$0.55-0.75B (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027), and ~62-65M shares outstanding.
Deep-Dive 1: EDG-5506-Sevasemten-Muscular-Dystrophy-and-EDG-7500-Cardiomyopathy Franchise
The first deep-dive — EDG-5506-Sevasemten + EDG-7500 + Clinical-Stage-Pipeline-Cardiomyopathy-and-Muscular-Dystrophy franchise — covers entire EDG-5506-Sevasemten-Muscular-Dystrophy-Becker-and-DMD-Phase-3 + multi-cycle-emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2 + multi-cycle-emerging-Discovery-Pipeline business + distinctive multi-cycle Edgewise-Therapeutics-and-emerging-multi-cycle-Edgewise-Therapeutics positioning.
Geographic + Employee composition: distinctive multi-cycle ~~100-130 employees + ~~Boulder-CO-HQ-Clinical-Development-Biotech-Office providing distinctive multi-cycle Edgewise-Therapeutics-and-emerging-multi-cycle-Edgewise-Therapeutics across US (Boulder-CO-HQ + Multi-Clinical-Trial-Site-US) + emerging multi-jurisdiction-international (Multi-Clinical-Trial-Site-Europe-and-Canada).
Revenue mix:
- Clinical-Stage-Biotech-Pipeline (~~0% pre-Commercial-Biotech-revenue, pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development + multi-cycle-emerging-EDG-5506-Sevasemten-Muscular-Dystrophy-Becker-and-DMD-Phase-3 + multi-cycle-emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2 + multi-cycle-emerging-Discovery-Pipeline).
- Emerging-Other-Collaboration-and-Grant (~~0-1% pre-Commercial-Biotech-revenue).
Customer base: Pre-Commercial-Biotech-Clinical-Development (no customer base, pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development + multi-cycle-emerging-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Patient-and-Physician-and-Health-Plan-target + multi-cycle-emerging-Becker-Muscular-Dystrophy-BMD-Patient-Population ~~10,000-15,000 US-Patient + multi-cycle-emerging-Duchenne-Muscular-Dystrophy-DMD-Patient-Population ~~10,000-15,000 US-Patient + multi-cycle-emerging-Hypertrophic-Cardiomyopathy-HCM-Patient-Population ~~700,000+ US-Patient-and-International).
Distinctive multi-cycle 2017-Edgewise-Therapeutics-Kevin-Koch-Founder + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension transformational-platform.
Emerging structural-tailwinds: emerging-multi-cycle US-and-emerging-multi-cycle-international-Clinical-Stage-Biotech (substantial multi-cycle-emerging-Muscular-Dystrophy-Becker-and-DMD-Therapeutic-Market + emerging-multi-cycle-Hypertrophic-Cardiomyopathy-HCM-Therapeutic-Market + emerging-multi-cycle-Mavacamten-Bristol-Myers-Squibb-BMY-Camzyos-Approved-HCM-Reference + emerging-multi-cycle-Aficamten-Cytokinetics-CYTK-Phase-3-HCM-emerging-Approval + emerging-multi-cycle-Sarepta-SRPT-Elevidys-DMD-Gene-Therapy-Approved + emerging-multi-cycle-Italfarmaco-ITF-IT-Givinostat-DMD-Approved-Histone-Deacetylase-Inhibitor + emerging-multi-cycle-Biotech-M&A-Activity-Large-Pharma-Acquisition-of-Late-Stage-Biotech) demand environment.
FY2026 catalyst is EDG-5506-Sevasemten-Phase-3-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne-Clinical-Trial-Readout + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Clinical-Trial-Readout + emerging-Pipeline-Advancement + Kevin-Koch-Founder-CEO-strategic-execution.
Competes in Cardiomyopathy-and-Muscular-Dystrophy-Therapeutic space with Sarepta Therapeutics (SRPT + Sarepta-Elevidys-DMD-Gene-Therapy-Approved + 2024-Sarepta-Elevidys-Label-Expansion + 2024-Sarepta-emerging-Roche-RHHBY-Elevidys-Ex-US-Partner + 2024-Sarepta-Elevidys-Adolescent-and-Older-Boys-Label-Expansion), Bristol-Myers Squibb (BMY + Bristol-Myers-Squibb-Camzyos-Mavacamten-HCM-Approved + 2022-Camzyos-Approved-FDA + 2024-Camzyos-Class-Effect-Heart-Failure-emerging-Sales), Cytokinetics (CYTK + Cytokinetics-Aficamten-HCM-Phase-3-emerging-Approval + 2024-Cytokinetics-Aficamten-Phase-3-SEQUOIA-HCM-Positive-Readout + 2024-Cytokinetics-emerging-Approval-Aficamten-2025-PDUFA), Italfarmaco (ITF-IT-private + Italfarmaco-Givinostat-DMD-Approved-Histone-Deacetylase-Inhibitor + 2024-Italfarmaco-Givinostat-FDA-Approved-DMD), PTC Therapeutics (PTCT + PTC-Therapeutics-Translarna-DMD + PTC-Vatiquinone-Friedreich-Ataxia + 2024-PTC-Therapeutics-emerging), Capricor Therapeutics (CAPR + Capricor-Therapeutics-Deramiocel-DMD-Cardiomyopathy + 2024-Capricor-emerging-BLA-Filing-Deramiocel-DMD + Nippon-Shinyaku-Japanese-Partner), Solid Biosciences (SLDB + Solid-Biosciences-SGT-003-DMD-Gene-Therapy-Phase-1-2), REGENXBIO (RGNX + REGENXBIO-RGX-202-DMD-Gene-Therapy-Phase-1-2), Catabasis Pharmaceuticals (Astria-Therapeutics-ATXS-acquired 2021 + Catabasis-DMD-Edasalonexent + Catabasis-Discontinued), Wave Life Sciences (WVE + Wave-Life-Sciences-DMD-and-Cardiomyopathy + 2024-Wave-emerging), Stoke Therapeutics (STOK + Stoke-Therapeutics-Dravet-Syndrome-and-Genetic-Disease), MyoKardia (Bristol-Myers-Squibb-BMY-acquired 2020 + MyoKardia-Camzyos-Mavacamten-HCM-acquired-by-Bristol-Myers), Tenaya Therapeutics (TNYA + Tenaya-Therapeutics-Heart-Failure-and-Cardiomyopathy + 2024-Tenaya-emerging), Lexeo Therapeutics (LXEO + Lexeo-Therapeutics-Cardiomyopathy-Gene-Therapy + 2024-Lexeo-emerging-Cardiomyopathy-Friedreich-Ataxia-Phase-1-2), BioMarin (BMRN + BioMarin-Roctavian-Hemophilia-A-Gene-Therapy + 2024-BioMarin-Skill-Lab-emerging + 2024-BioMarin-emerging-DMD-emerging-CCM-DMD-Phase-1-2-Voxzogo); Larger-Cap-Biotech-M&A-Acquirer Pfizer (PFE + Pfizer-2023-Seagen-acquired-$43B), Merck (MRK + Merck-Prometheus-Biosciences-acquired 2023 + Merck-Acceleron-Pharma-acquired 2021), AbbVie (ABBV + AbbVie-Cerevel-Therapeutics-acquired 2024 + AbbVie-ImmunoGen-acquired 2024), Bristol-Myers Squibb (BMY + Bristol-Myers-Squibb-Karuna-Therapeutics-acquired 2024 + Bristol-Myers-Squibb-Mirati-Therapeutics-acquired 2024 + Bristol-Myers-Squibb-RayzeBio-acquired 2024), Eli Lilly (LLY + Eli-Lilly-Morphic-acquired 2024 + Eli-Lilly-DICE-Therapeutics-acquired 2023), Novartis (NVS + Novartis-Chinook-Therapeutics-acquired 2023 + Novartis-IFM-Due-acquired 2023), Sanofi (SNY + Sanofi-Provention-Bio-acquired 2023), AstraZeneca (AZN + AstraZeneca-Alexion-acquired 2021 + AstraZeneca-CinCor-acquired 2023 + AstraZeneca-Gracell-acquired 2024 + AstraZeneca-Amolyt-Pharma-acquired 2024); private-equity-Biotech Flagship Pioneering (private + Flagship-Pioneering-Biotech-Incubator-Largest), ARCH Venture Partners (private + ARCH-Venture-Partners-Biotech-Largest), Third Rock Ventures (private + Third-Rock-Biotech-Largest), Atlas Venture (private + Atlas-Venture-Biotech-Largest), Polaris Partners (private + Polaris-Partners-Biotech-and-Tech), Versant Ventures (private + Versant-Ventures-Biotech-Largest), OrbiMed Advisors (private + OrbiMed-Biotech-Largest), RA Capital Management (private + RA-Capital-Biotech-Crossover-Largest), Baker Bros Advisors (private + Baker-Bros-Biotech-Largest), Perceptive Advisors (private + Perceptive-Advisors-Biotech-Largest), Foresite Capital (private + Foresite-Capital-Biotech-Crossover), Avoro Capital Advisors (private + Avoro-Capital-Biotech-Crossover).
Deep-Dive 2: Kevin-Koch + Founder-CEO + Multi-Decade Compounder Thesis
The second deep-dive — Kevin-Koch + Founder-CEO-since-2017 + Founder-Edgewise-Therapeutics-Co-Founder + multi-decade compounder thesis — covers distinctive multi-cycle Kevin-Koch-Founder-CEO (~30+ year longtime-Former-Array-Biopharma-and-Tecan-and-Genentech-veteran) expertise + Founder-Edgewise-Therapeutics-Co-Founder leadership-continuity, 2017-Edgewise-Therapeutics-founding + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts transformational-platform + multi-cycle-disciplined-Clinical-Stage-Pipeline-Advancement, emerging-multi-cycle US-and-international-Clinical-Stage-Biotech + emerging-Muscular-Dystrophy-Becker-and-DMD-Therapeutic-Market + emerging-Hypertrophic-Cardiomyopathy-HCM-Therapeutic-Market structural-tailwinds.
Kevin Koch Founder-CEO leadership: Founder-CEO since 2017-Founder-CEO + Founder-Edgewise-Therapeutics-Co-Founder + ~30+ year longtime-Former-Array-Biopharma-and-Tecan-and-Genentech-veteran providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 2017-Founder-CEO + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts execution + multi-cycle-Muscular-Dystrophy-Becker-and-DMD-Therapeutic-Market + emerging-Hypertrophic-Cardiomyopathy-HCM-Therapeutic-Market expertise.
2017-Edgewise-Therapeutics-Founder + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-Clinical-Trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension transformational-platform: distinctive substantial 2017-Edgewise-Therapeutics-Kevin-Koch-Founder-and-Co-Founder + 2019-Series-B-Financing + 2020-NASDAQ-Edgewise-Therapeutics-IPO ($175M proceeds providing distinctive Public-Listing-and-Clinical-Development-Funding) + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts providing distinctive multi-cycle Edgewise-Therapeutics-and-emerging-multi-cycle-Edgewise-Therapeutics.
No-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn): distinctive no-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn).
Multi-decade compounder thesis combines distinctive multi-cycle Edgewise-Therapeutics-and-Boulder-CO ~8+ year heritage (founded 2017 + 2020 NASDAQ-IPO + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts), ~100-130 employees + ~Boulder-CO-HQ-Clinical-Development-Biotech-Office, 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension, Kevin Koch + Founder-CEO + Former-Array-Biopharma-and-Tecan-and-Genentech expertise, no-dividend + Pre-Commercial-Biotech-Cash-Runway-into-2027 + Pre-Commercial-Biotech-Clinical-Development-Burn balance-sheet, emerging-EDG-5506-Sevasemten-Phase-3-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne-Clinical-Trial-Readout + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Clinical-Trial-Readout structural-tailwinds.
Consolidated Capital Position + Balance Sheet
Capital position is Pre-Commercial-Biotech (Not-Rated-Pre-Commercial-Biotech), no-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn), conservative-Pre-Commercial-Biotech-Cash-Runway-into-2027-focused: net cash ~$0.55-0.75B (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027), Not-Rated-Pre-Commercial-Biotech equivalent, $0.55-0.75B cash + Pre-Commercial-Biotech-Cash-Runway-into-2027, no-dividend + no-buyback + emerging-Pre-Commercial-Biotech-Clinical-Development-Burn ~$-180 to -125M/yr Clinical-Development-Burn + multi-cycle-disciplined-Clinical-Stage-Pipeline-Advancement, ~62-65M shares.
Key Core Metrics
| Metric | FY2025E Range | Notes |
|---|---|---|
| Revenue | ~$0M | Pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development |
| Revenue YoY Growth | n/a | Pre-Commercial-Biotech-Clinical-Development |
| Adjusted EBITDA | ~$-180 to -125M | Pre-Commercial-Biotech-Clinical-Development-Burn |
| Adjusted EPS | ~$-2.95 to -2.05 | Pre-Commercial-Biotech-loss |
| Cash + Equivalents | ~$0.55-0.75B | Multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027 |
| Employee Count | ~100-130 | Boulder-CO-HQ + Multi-Clinical-Trial-Site-US-and-Europe-and-Canada |
| Clinical-Stage-Biotech-Pipeline | ~0% revenue | Pre-Commercial-Biotech-Phase-3-EDG-5506-and-Phase-2-EDG-7500 |
| Net Cash | ~$0.55-0.75B | Multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027 |
| Credit Rating | Not-Rated | Pre-Commercial-Biotech |
| Dividend | None | Pre-Commercial-Biotech-Clinical-Development-Burn |
| Buyback | None | Pre-Commercial-Biotech-Clinical-Development-Burn |
| Shares Outstanding | ~62-65M | Pre-Commercial-Biotech-Public-Listing |
| Becker Muscular Dystrophy US Patient Population | ~10,000-15,000 | EDG-5506-Sevasemten Phase 3 target |
| Hypertrophic Cardiomyopathy HCM US Patient Population | ~700,000+ | EDG-7500 Phase 2 target |
Market Evaluation
At ~$22-32 per share, equity value ~$1.4-2.05B, providing Pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development-and-Phase-3-Clinical-Trial-Readout-Option-Value-and-Phase-2-Clinical-Trial-Readout-Option-Value-and-Cash-Runway-Per-Share-Value-Anchored — typical-mid-cap-Pre-Commercial-Biotech-Phase-3 multiple consistent with multi-cycle 2017-Edgewise-Therapeutics-founding + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension + 2024-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts + emerging-multi-cycle Muscular-Dystrophy-Becker-and-DMD-Therapeutic-Market + emerging-Hypertrophic-Cardiomyopathy-HCM-Therapeutic-Market + emerging-Biotech-M&A-Activity tailwinds.
Base case: EDG-5506-Sevasemten-Phase-3-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne-Clinical-Trial-Readout-Positive + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Clinical-Trial-Readout-Positive + Pre-Commercial-Biotech-Cash-Runway-into-2027-maintained + ~0-30% return (Pre-Commercial-Biotech-Phase-3-Clinical-Trial-Readout-Option-Value).
Bull case: EDG-5506-Sevasemten-Phase-3-Positive-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Positive-Substantially-Inflects + Pre-Commercial-Biotech-FDA-Approval-Pathway + Commercial-Launch + selective-M&A + emerging-strategic-acquisition-target (Sarepta + Bristol-Myers-Squibb + Cytokinetics + Italfarmaco + PTC-Therapeutics + Capricor + Solid + REGENXBIO + Wave + Stoke + Tenaya + Lexeo + BioMarin + Larger-Cap-Biotech-M&A-Pfizer-Merck-AbbVie-BMY-Lilly-Novartis-Sanofi-AstraZeneca + private-equity-Flagship-ARCH-Third-Rock-Atlas-Polaris-Versant-OrbiMed-RA-Capital-Baker-Bros-Perceptive-Foresite-Avoro interest) + re-rate 4-10x + 100-400%+ return + takeout-premium-upside.
Bear case: EDG-5506-Sevasemten-Phase-3-Negative + EDG-7500-Phase-2-Negative + Pre-Commercial-Biotech-Clinical-Development-disappoints + Cash-Runway-stresses + -50% to -85% return + Pre-Commercial-Biotech-Cash-Per-Share-Value-Anchored.
FY2026 turns on EDG-5506-Sevasemten-Phase-3-Cardiomyopathy-and-Muscular-Dystrophy-Becker-and-Duchenne-Clinical-Trial-Readout + emerging-EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2-Clinical-Trial-Readout + emerging-Pipeline-Advancement + Kevin-Koch-Founder-CEO-strategic-execution.
Word count: 2010